Owing to constant developments and challenges in the life sciences industry, stakeholders must continue to be adaptable, innovative, and competitive to thrive. Industry leaders must reconsider their strategic positions annually by understanding the main forces behind the transformation, including potential, challenges, and drivers.Key Challenges, Trends, and Changes Transforming the Life Sciences Industry
This analysis explores the strategic imperatives shaping and transforming the life sciences industry. They are as follows: SaaS evolution provides adaptive intelligence for laboratoriesCDMOs augment competencies in new modalities, and digital transformation delivers end-to-end partnershipsExpanding direct-to-consumer (DTC) genetic testing beyond ancestry testing to multi-pathogenic STIsUncertainty about trade wars disrupts pharmaceutical supply chains Decentralized clinical trials (DCTs) boost efficiency for CGTs and rare disordersNext-generation sequencing (NGS) and liquid biopsy revolutionize oncology diagnosticsFailed clinical trials and shifting market conditions setback biotech innovationESG initiatives climb to the top of CEOs' strategic prioritiesReal-world insight (RWI) emerges as a strategic compass point to reimagine commercial strategiesCRISPR technology advances biologics R&D
Table of Contents
Strategic Imperatives- Why is it Increasingly Difficult to Grow?
- The Strategic Imperative 8™
- Top Transformations Impacting the Growth of the Life Sciences Industry
- Key Industry Trends and Challenges
- Transformation 1: SaaS Evolution Provides Adaptive Intelligence for Laboratories
- Transformation 2: CDMOs Augment Competencies in New Modalities, and Digital Transformation Delivers End-to-End Partnerships
- Transformation 3: Expanding Direct-to-Consumer (DTC) Genetic Testing Beyond Ancestry Testing to Multi-pathogenic STIs
- Transformation 4: Uncertainty About Trade Wars Disrupts Pharmaceutical Supply Chains
- Transformation 5: Decentralized Clinical Trials (DCTs) Boosting Efficiency for CGTs and Rare Disorders
- Transformation 6: Next-generation Sequencing (NGS) and Liquid Biopsy Revolutionize Oncology Diagnostics
- Transformation 7: Failed Clinical Trials and Shifting Market Conditions Setback Biotech Innovation
- Transformation 8: ESG Initiatives Climb to the Top of CEOs' Strategic Priorities
- Transformation 9: Real-world Insight (RWI) Emerges as a Strategic Compass Point to Reimagine Commercial Strategies
- Transformation 10: CRISPR Technology Advances Biologics R&D
- Analytics Perspectives
- Benefits and Impacts of Growth Opportunities
- Next Steps
- Legal Disclaimer
